How does the mRNA/lipid nanoparticle platform promote protective adaptive immunity against SARS-CoV-2? news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines
Lipid nanoparticles (LNPs) are the carrier vehicles that protect messenger RNA (mRNA) molecules from degradation and aid intracellular delivery and endosomal escape in the nucleoside-modified mRNA-LNP vaccine platforms currently used by Pfizer/BioNTech and Moderna, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These two vaccines surpass the rest with their effective support for T follicular helper cells (Tfh) and the protective humoral responses observed in the preclinical trials.
While the vital role of LNPs in these vaccines action is established, the potentially inflammatory nature of these LNPs is not assessed. Also, in the Pfizer/BioNTech and Moderna vaccines human trials, it is reported that side effects often linked to inflammation, such as pain, swelling, fever, and sleepiness, are common.